Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study

Hemophilia is characterized by a compromised hemostatic response with delayed development of a clot and the formation of clots that are vulnerable to fibrinolysis. We proposed to study, in vitro and in factor VIII knockout mice (FVIII‐KO), whether hemostasis is improved with the addition of tranexamic acid (TXA) to low FVIII plasma concentrations.

• Publication year

  2019

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2019-11-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jth.14694PMID 31782901
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tranexamic acid may benefit patients undergoing total hip/knee arthroplasty because of haemophilia

  2019cited by this paper
• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.

  2019cited by this paper
• Intravenous and Topical Tranexamic Acid Alone Are Superior to Tourniquet Use for Primary Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial

  2017cited by this paper
• Design and characterization of an APC-specific serpin for the treatment of hemophilia.

  2017cited by this paper
• Multiple Boluses of Intravenous Tranexamic Acid to Reduce Hidden Blood Loss After Primary Total Knee Arthroplasty Without Tourniquet: A Randomized Clinical Trial.

  2016cited by this paper
• Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions

  2015cited by this paper
• Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.

  2015cited by this paper
• An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A

  2014cited by this paper
• Guidelines for the management of hemophilia

  2013cited by this paper
• Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)

  2013cited by this paper
• A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management

  2012cited by this paper
• Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial

  2012cited by this paper
• Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A – a two‐centre experience

  2012cited by this paper
• A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

  2011cited by this paper
• Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty

  2011cited by this paper
• High-dose tranexamic acid reduces blood loss in postpartum haemorrhage

  2011cited by this paper
• Tranexamic acid in hip fracture surgery: a randomized controlled trial.

  2010cited by this paper
• Towards a standardization of the murine tail bleeding model

  2010cited by this paper
• Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.

  2010cited by this paper
• Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations

  2009cited by this paper
• Thrombin generation, fibrin clot formation and hemostasis.

  2008cited by this paper
• Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.

  2007cited by this paper
• Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A

  2007cited by this paper
• Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B

  2005cited by this paper
• The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX

  2003cited by this paper
• The dynamics of thrombin formation.

  2003cited by this paper
• The Defective Down Regulation of Fibrinolysis in Haemophilia A Can Be Restored by Increasing the TAFI Plasma Concentration

  2001cited by this paper
• Effect of fibrin structure on plasmin-mediated dissolution of plasma clots.

  1995cited by this paper
• A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs

  1994cited by this paper

• Use of crushed tranexamic acid tablets in water for paediatric patients with bleeding disorders

  2024cites this paper
• Differences in venous clot structures between hemophilic mice treated with emicizumab versus factor VIII or factor VIIIFc

  2023cites this paper
• Tranexamic acid is safe with respect to the risk of deep venous thrombosis in patients with hemophilic arthritis undergoing total knee arthroplasty without chemoprophylaxis: A prospective study.

  2023cites this paper
• Blood-Induced Arthropathy: A Major Disabling Complication of Haemophilia

  2023cites this paper
• Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes

  2022cites this paper
• Low dose prophylaxis and antifibrinolytics: Options to consider with proven benefits for persons with haemophilia

  2022cites this paper
• Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study

  2021cites this paper
• Tranexamic acid-loaded hemostatic nanoclay microsphere frameworks.

  2021cites this paper
• Hemophilia and fibrinolysis system

  2020cites this paper